| Literature DB >> 33866970 |
Claudio F Feo1, Giulia Deiana2, Chiara Ninniri2, Giuseppe Cherchi2, Paola Crivelli3, Alessandro Fancellu2, Giorgio C Ginesu2, Alberto Porcu2.
Abstract
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with poor prognosis. Radical surgery is the best option for cure and, nowadays, it is performed by many surgeons also in cases of vascular infiltration. Whether this aggressive approach to a locally advanced PDAC produces a survival benefit is under debate. Most data in the literature come from retrospective comparative studies; therefore, it is still unclear if such an extensive surgery for an advanced cancer is justified.Entities:
Keywords: Arterial infiltration; Pancreatic ductal adenocarcinoma; Pancreatic surgery; Prognosis; Survival; Venous infiltration
Year: 2021 PMID: 33866970 PMCID: PMC8054428 DOI: 10.1186/s12957-021-02238-x
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Patients’ characteristics
| Overall ( | VR− group ( | VR+ group ( | ||
|---|---|---|---|---|
| Age (years), mean | 68.7±10.8 | 68.6±11.1 | 69±10.0 | 0.850 |
| Male/female | 84/89 | 67/65 | 17/24 | 0.298 |
| BMI (kg/m2), mean | 25.9±3.9 | 26.6±3.9 | 23±3.8 | 0.063 |
| ASA class | ||||
| I–II (%) | 85 (49.1) | 61 (46.2) | 24 (58.5) | 0.168 |
| III (%) | 88 (50.9) | 71 (53.8) | 17 (41.5) | 0.168 |
| Comorbidities | ||||
| Diabetes (%) | 24 (13.9) | 16 (12.1) | 8 (19.5) | 0.232 |
| Cardiovascular disease (%) | 25 (14.5) | 20 (15.2) | 5 (12.2) | 0.638 |
| COPD (%) | 2 (1.2) | 2 (1.5) | 0 | 0.428 |
| Obstructive jaundice (%) | 43 (24.9) | 25 (18.9) | 18 (43.9) | |
| Preoperative biliary drainage (%) | 20 (11.6) | 10 (7.6) | 10 (24.4) | |
| Tumour stage | ||||
| I (%) | 47 (27.2) | 39 (29.5) | 8 (19.5) | 0.207 |
| II (%) | 70 (40.5) | 55 (41.7) | 15 (36.6) | 0.563 |
| III (%) | 47 (27.2) | 32 (24.2) | 15 (36.6) | 0.121 |
| IV (%) | 9 (5.2) | 6 (4.5) | 3 (7.3) | 0.485 |
| Degree of tumour contact at CT | ||||
| < 180° (%) | 31 (17.9) | – | 31 (75.6) | |
| > 180° (%) | 10 (5.8) | – | 10 (24.4) | |
BMI body mass index, ASA American Society of Anesthesiologists, COPD chronic obstructive pulmonary disease, CT computed tomography
Operative and postoperative details
| Overall ( | VR− group ( | VR+ group ( | ||
|---|---|---|---|---|
| Operative time (minutes), mean | 309.2±93.2 | 295.1±96.3 | 343.9±75.6 | |
| Type of operation | ||||
| Whipple PD (%) | 53 (30.6) | 43 (32.6) | 10 (24.4) | 0.321 |
| Traverso-Longmire PD (%) | 65 (37.6) | 52 (39.4) | 13 (31.7) | 0.375 |
| Distal splenopancreatectomy (%) | 25 (14.5) | 20 (15.2) | 5 (12.2) | 0.638 |
| Total pancreatectomy (%) | 30 (17.3) | 17 (12.9) | 13 (31.7) | |
| Type of vascular resection | ||||
| Venous (%) | 37 (21.4) | – | 37 (90.2) | |
| Arterial (%) | 2 (1.2) | – | 2 (4.9) | |
| Arteria/venous (%) | 2 (1.2) | – | 2 (4.9) | |
| Type of vessel reconstruction | ||||
| Direct suture (%) | 32 (18.5) | – | 32 (78) | |
| Autologous venous patch (%) | 1 (0.6) | – | 1 (2.4) | |
| Autologous venous segment (%) | 8 (4.6) | – | 8 (19.5) | |
| Intraoperative blood transfusion (%) | 48 (27.7) | 26 (19.7) | 22 (53.7) | |
| ICU stay (days), mean | 1±2.3 | 0.7±1.6 | 1.4±3.0 | 0.187 |
| Clavien-Dindo class | ||||
| I (%) | 10 (26) | 7 (28) | 3 (19.5) | 0.629 |
| II (%) | 30 (17.3) | 15 (11.4) | 15 (36.6) | 0.000 |
| III (%) | 14 (8.1) | 8 (6.1) | 6 (14.6) | 0.079 |
| IV (%) | 2 (1.2) | 1 (0.8) | 1 (2.4) | 0.379 |
| Overall complications | 56 (32.4) | 31 (23.5) | 25 (61) | |
| Pancreas-specific complications | ||||
| POPF (%) | 19 (11) | 15 (11.4) | 4 (9.8) | 0.774 |
| Haemorrhage (%) | 9 (5.2) | 3 (2.3) | 6 (14.6) | |
| Delayed gastric emptying (%) | 5 (2.9) | 2 (1.5) | 3 (7.3) | 0.053 |
| Reoperation (%) | 13 (7.5) | 7 (5.3) | 6 (14.6) | |
| Hospital stay (days), mean | 18.6±12.6 | 18.9±14.0 | 18.3±10.5 | 0.684 |
| 90-day mortality (%) | 21 (12.1) | 15 (11.4) | 6 (14.6) | 0.575 |
PD pancreaticoduodenectomy, ICU intensive care unit, POPF postoperative pancreatic fistula
Oncological data
| Overall ( | VR− group ( | VR+ group ( | ||
|---|---|---|---|---|
| Tumour size (cm), mean | 3.1±1.2 | 2.8±1.0 | 3.5±1.2 | |
| Lymphovascular invasion (%) | 36 (20.8) | 24 (18.2) | 12 (29.3) | 0.127 |
| Perineural invasion (%) | 82 (47.4) | 57 (43.2) | 25 (61) | |
| Lymph node ratio, mean | 0.14±0.18 | 0.14±0.19 | 0.15±0.14 | 0.795 |
| Positive resection margins (%) | 13 (7.5) | 9 (6.8) | 4 (9.8) | 0.533 |
| Pathological vessel infiltration (%) | 32 (18.5) | – | 32 (78) | |
| Survival | ||||
| Overall (months), median | 17.7 (0.1–148.6) | 18.4 (0.1–148.6) | 15.4 (0.9–101.7) | 0.717 |
| 1 year (%) | 106 (61.3) | 81 (61.4) | 25 (61) | 0.964 |
| 3 years (%) | 36 (20.8) | 29 (22) | 7 (17.1) | 0.500 |
| 5 years (%) | 23 (13.3) | 19 (14.4) | 4 (9.8) | 0.445 |
Fig. 1Kaplan-Meier survival curves. Overall survival (P=0.717), VR− (red line) vs. VR+ (green line) group
Uni- and multivariate analysis
| Univariate | Multivariate | |
|---|---|---|
| Age ≥ 70 years | 90 (30.03) | |
| Male gender | 84 (33.96) 0.939 | 1.39 (0.90–2.13) |
| Whipple PD | 53 (28.49) 0.399 | 1.32 (0.86–2.05) |
| Postoperative complications | 56 (20.30) | |
| Tumour size ≥ 3 cm | 36 (38.49) 0.223 | 1.34 (0.87–2.07) |
| Lymphovascular invasion | 36 (37.09) 0.481 | 0.81 (0.44–1.47) |
| Perineural invasion | 82 (30.13) 0.545 | 1.47 (0.89–2.43) |
| Positive resection margins | 13 (26.62) 0.512 | 0.59 (0.26–1.32) |
| Vascular resection | 41 (25.52) 0.311 | 0.83 (0.48–1.45) |
PD pancreaticoduodenectomy, MST median survival time (months), HR hazard ratio, CI confidence interval